Queston #27425Note

In 2018, the FDA approved the purified cannabidiol oral solution (Epidiolex) for the treatment of Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older. It was also approved for tuberous sclerosis-related epilepsy in 2020 and is now approved for patients one year of age or older. Side effects include drowsiness and diarrhea. LFTs can increase with use and therefore should be monitored periodically.